Fundraising Fox

Invitrolize

Founded 2022 · 7 employees on LinkedIn · 1 known investors

Invitrolize develops 3D human alveolar in vitro models, including its patented ALIsens® system, to assess the respiratory safety of inhalable substances under air-liquid interface exposure conditions. It serves companies needing human-relevant respiratory sensitization and irritation data for regulatory dossiers and safety decisions, offering an alternative to animal testing.

BiotechDeep TechHealthtech

Investors · 1

Expon CapitalLuxembourg · $550K – $1.6M

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Invitrolize secures seed funding from Expon Capital - Startup Luxembourgstartupluxembourg.com · May 2025INVITROLIZE SECURES SEED INVESTMENT FROM EXPON CAPITAL TO EXPAND ALISENS® DEPLOYMENT ACROSS EUROPE AND THE US - Expon Capitalexponcapital.com · May 2025How I did my first fundraising: Turning science into strategy - Startup Luxembourgstartupluxembourg.com

Frequently asked questions

What does Invitrolize do?
Invitrolize develops 3D human alveolar in vitro models, including its patented ALIsens® system, to assess the respiratory safety of inhalable substances under air-liquid interface exposure conditions. It serves companies needing human-relevant respiratory sensitization and irritation data for regulatory dossiers and safety decisions, offering an alternative to animal testing.
Who are Invitrolize's investors?
Invitrolize's investors include Expon Capital.